Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com
Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com
(Get Rating)StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company's stock.
StockNews.com 开始报道的股票 Otonomy（纳斯达克股票代码：OTIC — 获取评级） 在周六上午发给投资者的研究报告中。该公司对这家生物制药公司的股票发布了持有评级。
Separately, Piper Sandler lowered shares of Otonomy from an overweight rating to a neutral rating and dropped their price target for the company from $3.00 to $0.50 in a research note on Thursday, October 13th.
另外，派珀·桑德勒在10月13日星期四的一份研究报告中将Otonomy的股票评级从增持评级下调至中性评级，并将该公司的目标股价从3.00美元下调至0.50美元。
Otonomy Price Performance
Otonomy 价格表现
Shares of Otonomy stock opened at $0.07 on Friday. The firm has a market capitalization of $4.23 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 52 week low of $0.06 and a 52 week high of $2.59. The firm's 50 day moving average is $0.11 and its two-hundred day moving average is $0.68.
周五，Otonomy股票开盘价为0.07美元。该公司的市值为423万美元，市盈率为-0.10，beta值为1.31。Otonomy创下52周低点0.06美元，52周高点2.59美元。该公司的50天移动平均线为0.11美元，其两百天移动平均线为0.68美元。
Hedge Funds Weigh In On Otonomy
对冲基金权衡自主权
Otonomy Company Profile
Otonomy 公司简介
(Get Rating)
（获取评分）
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Otonomy, Inc是一家生物制药公司，在美国开发神经病学疗法。该公司提供 OTO-313，一种持续暴露的N-甲基-D-天冬氨酸受体拮抗剂加环素配方，目前正在进行治疗耳鸣的II期临床试验；以及 OTO-413，一种大脑源性神经营养因子的持续暴露配方，正在进行用于修复耳蜗突触病和治疗噪音中言语听力障碍的IIa期临床试验。
See Also
另见
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- 免费获取 StockNews.com 关于自主学的研究报告（OTIC）的副本
- 新年值得关注的三只医疗保健细价股
- 西南航空股票，有很多值得爱的地方
- MarketBeat：本周回顾 12 月 19 日 — 12 月 23 日
- 这些钢铁制造商值得在你的 2023 年观察名单上占有一席之地
- 通货膨胀降温，标准普尔500指数现在走向何方
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。
